- Origin Therapeutics portfolio company, Clairvoyant Therapeutics, has received regulatory approval to proceed with the company’s Phase 2 clinical trial in Finland
- Clairvoyant Therapeutics is investigating the use of psilocybin for the treatment of alcohol use disorder (AUD)
- The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus a placebo
- Clairvoyant Therapeutics is a Canadian biotechnology company
- Origin Therapeutics Holdings Inc is an investment company focusing on investments in the psychedelic industry
- Origin Therapeutics Holdings Inc. (ORIG) opened trading at C$0.045
Origin Therapeutics Holdings’ (ORIG) portfolio company, Clairvoyant Therapeutics, has received regulatory approval to proceed with the company’s Phase 2 clinical trial.
The regulatory approval to investigate psilocybin for the treatment of alcohol use disorder (AUD) was granted by the Finnish Medicines Agency (FIMEA).
The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus a placebo with Motivational Enhancement Therapy (MET). Following the approval from FIMEA, Clairvoyant has launched the first of four planned trial sites in Finland. In total, the clinical trial will be initiated in approximately 15 sites across Canada, and Europe, with the first site in Canada, initiated in June of 2022. Several potential patients have already entered the screening process for the trial.
“Clairvoyant’s goal is to obtain approval for AUD-related psilocybin therapy in Europe, the UK, and Canada by 2026, and they have taken another step toward achieving that goal,” stated Alex Somjen, CEO of Origin. “The team at Origin is really pleased with their progress thus far.”
Clairvoyant Therapeutics is a Canadian biotechnology company with a speed-to-market clinical strategy designed to enable psilocybin therapy in the E.U., the U.K., and Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026. Origin Therapeutics Holdings Inc is an investment company focusing on investments in the psychedelic industry.
Origin Therapeutics Holdings Inc. (ORIG) opened trading at C$0.045.